Alpha Cognition (ACOG) Fireside Chat summary
Event summary combining transcript, slides, and related documents.
Fireside Chat summary
3 Dec, 2025Introduction and agenda
Fireside chat format with pre-set questions and open Q&A for investors, focusing on commercial adoption and clinical development.
Current industry trends
Long-term care market for Alzheimer's is valued at $2.2 billion, with 15,000 nursing homes in the US, 5,000 specializing in Alzheimer's.
Most patients are switched from generics like Aricept due to side effects and loss of efficacy, with ZUNVEYL positioned as a better-tolerated alternative.
Challenges and overcoming obstacles
Inventory build remains choppy due to rapid growth and distributor adjustments, expected to normalize in two quarters.
Payer coverage is expanding gradually, with critical mass expected after three PBM contracts by 2026.
Adherence in nursing homes is high, but tolerability and polypharmacy remain key challenges.
Latest events from Alpha Cognition
- FDA-approved ZUNVEYL launches in March, targeting LTC Alzheimer's with improved tolerability.ACOG
Investor Update9 Jan 2026 - ZUNVEYL launched in US, $52.8M raised, and strong liquidity supports global expansion.ACOG
Q4 202427 Dec 2025 - Biopharma seeks up to $250M to fund Alzheimer's drug launch and pipeline, with $75M ATM offering.ACOG
Registration Filing16 Dec 2025 - 2.38M shares registered for resale; ZUNVEYL launch and Asia-Pacific deal drive growth.ACOG
Registration Filing16 Dec 2025 - ZUNVEYL's launch and Asia-Pacific licensing drive growth amid ongoing net losses and Nasdaq listing.ACOG
Registration Filing16 Dec 2025 - Key votes on board, auditor, and new equity plan highlight governance and compensation focus.ACOG
Proxy Filing2 Dec 2025 - Shareholders can request financial statements by mail or online for greater transparency.ACOG
Proxy Filing2 Dec 2025 - AGM to vote on directors, auditors, and 2025 stock plan; board recommends approval.ACOG
Proxy Filing2 Dec 2025 - IPO funds will support the U.S. launch of an Alzheimer's drug, but financial risks remain high.ACOG
Registration Filing29 Nov 2025